---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059408"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-05-12T20:15:50+00:00"
generated_at: "2026-05-12T20:47:26.347763+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%

## Summary
- No revenue for Q3 FY2026; R&D expenses $3.3M (up $1.4M YoY); G&A $5.1M (includes $2.5M impairment of IBIO-101 intangible).
- Cash, cash equivalents, and investments in debt securities $74.8M as of March 31, 2026; additional $17M from warrant exercises in Q4, extending cash runway into Q4 FY2028.
- Received regulatory clearance from Australia's TGA and HREC to initiate Phase 1 trial of IBIO-600 (anti-myostatin antibody) in overweight/obese adults; first dosing expected Q2 calendar 2026.
- Announced pipeline expansion into PH-HFpEF with a selective bispecific antibody blocking Activin A, GDF8, GDF11 to reduce cardiac fibrosis and vascular remodeling.
- Preclinical NHP data for IBIO-610: after two doses, visceral fat reduced by 6.7%, total fat mass by 5.2% (small, not statistically powered study).

## SEC filing metadata
- accession: 0001104659-26-059408
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-05-12T20:15:50+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/0001104659-26-059408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/ibio-20260512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059408
- JSON: https://secwatch.observer/filing/0001104659-26-059408.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059408.txt

## Key facts
- Earnings Releases
  iBio, Inc. reported financial results for third quarter ended Mar. 31, 2026.
  - Period: third quarter ended Mar. 31, 2026
  - Result: reported results
  source text: On May 12, 2026, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/0001104659-26-059408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.